Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I/II trial studies the best dose of erlotinib hydrochloride and to see how
well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver.
Erlotinib hydrochloride may help to inhibit the development of fibrous tissue and prevent
liver cancer from forming in patients with cirrhosis of the liver.